Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TRICARE Express Scripts Contract Gets OK From GAO

This article was originally published in The Pink Sheet Daily

Executive Summary

Express Scripts offered the least disruption and second-lowest "total expected government cost" in its bid for TRICARE's pharmacy services contract. The Comptroller General denies protests filed by four other bidders.

You may also be interested in...



Express Scripts Says TRICARE Program Running Smoothly After Start-Up "Glitch"

Software problem delayed claims after June 1 start date of Department of Defense contract, Express Scripts acknowledges. "Very complex" program changes were also a challenge, but everything is "normal" as of June 10.

Express Scripts Says TRICARE Program Running Smoothly After Start-Up "Glitch"

Software problem delayed claims after June 1 start date of Department of Defense contract, Express Scripts acknowledges. "Very complex" program changes were also a challenge, but everything is "normal" as of June 10.

TRICARE Formulary Sets Broad Definition Of Therapeutic Class

Categories for formulary inclusion will be defined by "clinical use," a DoD final rule states. A pharmaceutical manufacturer had suggested that the classes be defined by "relevant drug receptors."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel